NASDAQ: SEPNSepterna Inc Stock
$5.90-0.09 (-1.5%)
Updated Apr 17, 2025
SEPN Price
$5.90
Fair Value Price
$1.91
Market Cap
$262.21M
52 Week Low
$4.17
52 Week High
$28.99
P/E
-0.81x
P/B
0.62x
P/S
210.7x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.08M
Earnings
-$71.80M
Gross Margin
100%
Operating Margin
-6,725.21%
Profit Margin
-6,678.9%
Debt to Equity
0.09
Operating Cash Flow
-$67M
Beta
1.3
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SEPN Overview
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SEPN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SEPN
Ranked#181 of 463
Ranked#181 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important SEPN news, forecast changes, insider trades & much more!
SEPN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SEPN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SEPN ($5.90) is overvalued by 209.14% relative to our estimate of its Fair Value price of $1.91 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SEPN ($5.90) is not significantly undervalued (209.14%) relative to our estimate of its Fair Value price of $1.91 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SEPN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SEPN due diligence checks available for Premium users.
Valuation
SEPN fair value
Fair Value of SEPN stock based on Discounted Cash Flow (DCF)
Price
$5.90
Fair Value
$1.91
Overvalued by
209.14%
SEPN ($5.90) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SEPN ($5.90) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SEPN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SEPN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.81x
Industry
-177.72x
Market
27.98x
SEPN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.62x
Industry
4.05x
SEPN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SEPN's financial health
Profit margin
Revenue
$212.0k
Net Income
-$20.7M
Profit Margin
-9,749.1%
SEPN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SEPN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$456.6M
Liabilities
$36.5M
Debt to equity
0.09
SEPN's short-term assets ($356.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SEPN's short-term assets ($356.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SEPN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$21.0M
Investing
-$133.2M
Financing
$304.2M
SEPN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SEPN vs Biotech Stocks
Septerna Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.